WESTCORT (hydrocortisone valerate) by PharmaIN is clinical pharmacology like other topical corticosteroids, hydrocortisone valerate has anti-inflammatory, antipruritic and vasoconstrictive properties. First approved in 1978.
Drug data last refreshed 18h ago · AI intelligence enriched 1w ago
WESTCORT (hydrocortisone valerate) is a medium-potency topical corticosteroid cream approved in 1978 for inflammatory and pruritic skin conditions. It works by inhibiting phospholipase A2, suppressing prostaglandin and leukotriene biosynthesis to reduce inflammation, itching, and vasodilation. The drug is absorbed through intact and compromised skin, with penetration enhanced by occlusive dressings.
This product is approaching loss of exclusivity in a mature, competitive topical corticosteroid market with moderate competitive pressure (30/100), suggesting defensive positioning and focus on brand loyalty and formulation differentiation rather than expansion.
CLINICAL PHARMACOLOGY Like other topical corticosteroids, hydrocortisone valerate has anti-inflammatory, antipruritic and vasoconstrictive properties. The mechanism of the anti-inflammatory activity of the topical steroids, in general, is unclear. However, corticosteroids are thought to act by the…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on WESTCORT at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on WESTCORT offers limited growth trajectory but provides solid experience in mature product management, generic defense strategies, and cost-based competition in a crowded topical market. This role suits professionals seeking stability and process-driven work rather than innovation-focused career development.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo